Plain-English translation of NCT07588152 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is studying how a medication called netarsudil works in the eye. Researchers want to see how this eye drop changes the tiny structures in your eye that drain fluid, using special high-powered imaging. This will help doctors better understand how the medication lowers eye pressure.
High eye pressure is a major cause of vision loss and blindness in glaucoma, and it happens because fluid isn't draining well from the eye. While laboratory studies suggest this medication helps improve drainage, doctors don't have clear pictures of exactly how it changes the eye's drainage system in real patients — and this study aims to fill that gap.
You likely qualify if…
You likely don't qualify if…
You will receive either the netarsudil eye drops or artificial tears (placebo) to use once daily in the evening for about 2 weeks. You'll have detailed eye imaging at the start of the study and again after 14–21 days using advanced cameras that take very close-up pictures of your eye's drainage system. The study takes about 2–3 weeks total, and the imaging procedures are non-invasive and painless.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States